Genecast RNA Fusion Focus is our proprietary gene fusion mutation detection reagent kit. It utilizes capture-based targeted RNA NGS sequencing to enhance detection sensitivity and targets a panel of 437 genes, comprehensively covering fusion mutations associated with pan-solid tumors and bone and soft tissue sarcomas, as recommended by the clinical practice guidelines of both NCCN and CSCO. In the context of sarcoma subtyping, Genecast RNA Fusion Focus also serves as a powerful complementary tool to traditional morphological methods.

Genecast RNA Fusion Focus exhibits good performance metrics comparable to leading domestic and international fusion detection assays and is applicable for low-quality or limited tissue samples. It is able to provide reliable molecular evidence to assist clinicians in diagnosis, therapy selection, and prognosis assessment. Genecast RNA Fusion Focus is supported by a proprietary bio-informatics analysis software suite, delivering high concordance with historical test results with the potential to identify potential novel gene fusions, thereby extending its clinical utility.

We obtained CE marking for Genecast RNA Fusion Focus in March 2022.